ORGO Q4 2023 Earnings — Organogenesis Holdings Inc. Revenue & Financial Results | Market Cap Arena

ORGOOrganogenesis Holdings Inc.

$355M

Q4 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$100M-13.7% YoY

Gross Profit

$72M72.1% margin

Operating Income

-$1M-1.3% margin

Net Income

-$568,000-0.6% margin

EPS (Diluted)

$-0.00

QoQ Revenue Growth

-8.2%

Cash Flow

Operating Cash Flow

$11M

Free Cash Flow

$7M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$460M

Total Liabilities

$181M

Stockholders' Equity

$279M

Cash & Equivalents

$104M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$100M	$116M	-13.7%
Gross Profit	$72M	$88M	-18.7%
Operating Income	-$1M	$9M	-114.6%
Net Income	-$568,000	$7M	-107.6%

Revenue Segments

Advanced Wound care

$93M93%

Surgical and Sports Medicine

$6M7%